Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 4
2006 2
2007 3
2008 4
2009 2
2010 2
2011 2
2014 4
2016 2
2018 2
2019 6
2020 13
2021 6
2022 8
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. Ledermann JA, et al. Among authors: clamp ar. Lancet Oncol. 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. Lancet Oncol. 2020. PMID: 32359490 Free PMC article.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, Coyle C, Blagden S, Brenton JD, Naik R, Perren T, Sundar S, Cook AD, Gopalakrishnan GS, Gabra H, Lord R, Dark G, Earl HM, Hall M, Banerjee S, Glasspool RM, Jones R, Williams S, Swart AM, Stenning S, Parmar M, Kaplan R, Ledermann JA. Clamp AR, et al. Lancet. 2019 Dec 7;394(10214):2084-2095. doi: 10.1016/S0140-6736(19)32259-7. Epub 2019 Nov 29. Lancet. 2019. PMID: 31791688 Free PMC article. Clinical Trial.
Antiangiogenic drugs in ovarian cancer.
Kumaran GC, Jayson GC, Clamp AR. Kumaran GC, et al. Among authors: clamp ar. Br J Cancer. 2009 Jan 13;100(1):1-7. doi: 10.1038/sj.bjc.6604767. Epub 2008 Nov 11. Br J Cancer. 2009. PMID: 19002176 Free PMC article. Review.
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD, McNeish IA, Cook AD, James EC, Lord R, Dark G, Glasspool RM, Krell J, Parkinson C, Poole CJ, Hall M, Gallardo-Rincón D, Lockley M, Essapen S, Summers J, Anand A, Zachariah A, Williams S, Jones R, Scatchard K, Walther A, Kim JW, Sundar S, Jayson GC, Ledermann JA, Clamp AR. Morgan RD, et al. Among authors: clamp ar. Lancet Oncol. 2021 Feb;22(2):277-288. doi: 10.1016/S1470-2045(20)30591-X. Epub 2020 Dec 22. Lancet Oncol. 2021. PMID: 33357510 Clinical Trial.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR, James EC, McNeish IA, Dean A, Kim JW, O'Donnell DM, Gallardo-Rincon D, Blagden S, Brenton J, Perren TJ, Sundar S, Lord R, Dark G, Hall M, Banerjee S, Glasspool RM, Hanna CL, Williams S, Scatchard KM, Nam H, Essapen S, Parkinson C, McAvan L, Swart AM, Popoola B, Schiavone F, Badrock J, Fananapazir F, Cook AD, Parmar M, Kaplan R, Ledermann JA. Clamp AR, et al. Lancet Oncol. 2022 Jul;23(7):919-930. doi: 10.1016/S1470-2045(22)00283-2. Epub 2022 Jun 9. Lancet Oncol. 2022. PMID: 35690073 Free PMC article. Clinical Trial.
Imaging angiogenesis of genitourinary tumors.
Zee YK, O'Connor JP, Parker GJ, Jackson A, Clamp AR, Taylor MB, Clarke NW, Jayson GC. Zee YK, et al. Among authors: clamp ar. Nat Rev Urol. 2010 Feb;7(2):69-82. doi: 10.1038/nrurol.2009.262. Epub 2010 Jan 19. Nat Rev Urol. 2010. PMID: 20084077 Review.
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. Morgan RD, et al. Among authors: clamp ar. Cancer Chemother Pharmacol. 2018 Apr;81(4):647-658. doi: 10.1007/s00280-018-3532-9. Epub 2018 Feb 20. Cancer Chemother Pharmacol. 2018. PMID: 29464354 Free PMC article. Review.
BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, Hasan J, Mitchell CL, Salih Z, Woodward ER, Lalloo F, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR. Morgan RD, et al. Among authors: clamp ar. Br J Cancer. 2022 Jul;127(1):163-167. doi: 10.1038/s41416-022-01773-y. Epub 2022 Mar 8. Br J Cancer. 2022. PMID: 35260807 Review.
First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD, Morgan RD, Edmondson RJ, Clamp AR, Jayson GC. Mahmood RD, et al. Among authors: clamp ar. Curr Oncol Rep. 2020 Jun 4;22(6):64. doi: 10.1007/s11912-020-00933-8. Curr Oncol Rep. 2020. PMID: 32494876 Free PMC article. Review.
Antiangiogenic therapy for ovarian cancer.
Rosa DD, Clamp AR, Collinson F, Jayson GC. Rosa DD, et al. Among authors: clamp ar. Curr Opin Oncol. 2007 Sep;19(5):497-505. doi: 10.1097/CCO.0b013e32827035f0. Curr Opin Oncol. 2007. PMID: 17762578 Review.
56 results